COGNITION THERAPEUTICS

Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease

05 7月 2023 06:30:06 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

28 6月 2023 06:00:00 条件 Nasdaq GlobeNewswire

Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023

27 6月 2023 18:17:07 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

20 6月 2023 06:30:15 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences

02 6月 2023 06:30:16 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

23 5月 2023 06:30:00 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

18 5月 2023 06:30:46 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

04 5月 2023 15:05:54 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

01 5月 2023 06:30:44 条件 Nasdaq GlobeNewswire

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

19 4月 2023 06:30:52 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

12 4月 2023 06:30:30 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

28 3月 2023 06:30:40 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

27 3月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

23 3月 2023 06:30:00 条件 Nasdaq GlobeNewswire

Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

21 3月 2023 07:00:32 条件 Nasdaq GlobeNewswire

UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 3月 2023 11:18:55 条件 Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 3月 2023 06:30:53 条件 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

15 3月 2023 06:30:16 条件 Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

07 3月 2023 07:00:13 条件 Nasdaq GlobeNewswire

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

22 2月 2023 07:00:02 条件 Nasdaq GlobeNewswire